HWA
ALNY icon

HHM Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

HHM Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$2.28K – 857
2025
Q2 		$2.28K Hold
7
– – ﹤0.01% 745
2025
Q1 		$1.89K Hold
7
– – ﹤0.01% 760
2024
Q4 		$1.65K Buy
+7
New +$1.84K ﹤0.01% 777

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

HHM Wealth Advisors's ALNY Position: Q3 2025 in Review

HHM Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 7 shares — an estimated $2.28K sold.

HHM Wealth Advisors first reported a position in ALNY in Q4 2024 and held it in 3 quarters. The position peaked at $2.28K in Q2 2025. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • HHM Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • HHM Wealth Advisors sold 7 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.28K.
  • HHM Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • HHM Wealth Advisors's Alnylam Pharmaceuticals position peaked at $2.28K in Q2 2025.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on HHM Wealth Advisors's 13F filing for Q3 2025, filed 29 Oct 2025.